Less than a tenth of people that would benefit from obesity jabs like Wegovy have access to them, caution the World Health Organization as it publishes its inaugural guidance on the therapies.
With in excess of 1,000,000,000 people worldwide now obese, it is urging more widespread and fairer availability to these injectable treatments.
According to projections, more than two billion will be living with obesity by 2030 unless action is taken.
"Our latest guidance acknowledges that obesity is a long-term condition that can be managed with holistic and lifelong support," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are key obstacles to universal access to the jabs that can aid individuals in losing significant body mass, notes the agency.
Skinny Jab Shortage
Even in the current most optimistic scenario, the production of GLP-1 therapies could only cover about 100 million people – less than 10% of eligible patients, per the health organization.
The guideline urges nations and manufacturers to expand access, through approaches such as licensing agreements.
A patent on the active ingredient – the main component of a leading brand – is due to expire in a number of countries in 2026.
The Way Weight-Loss Jabs Function
These medications mimick a biological compound to reduce digestion speed, reduce hunger and increase the sense of being full so users consume fewer calories.
People usually begin shedding pounds in the initial weeks of starting on the regular doses.
Research points to people may see weight return within a year of stopping the treatment, when their normal hunger resume.
Being carrying excess weight increases your chance for experiencing medical conditions, like diabetes, heart disease, stroke, and certain malignancies.
Obesity affects individuals in every country and was associated with 3.7 million fatalities worldwide in 2024, per the health agency.
